Phaseline

Targets › HRH3

HRH3 (Histamine H3 receptor): drug programs, companies and trials

2 programs from 2 companies in 5 trials: 4 Phase 3, 1 Phase 2; Neurology, Other, Psychiatry; next expected readout Apr 2027.

The H3 subclass of histamine receptors could mediate the histamine signals in CNS and peripheral nervous system. Signals through the inhibition of adenylate cyclase and displays high constitutive activity (spontaneous activity in the absence of agonist). (UniProt, Q9Y5N1)

Open in Phaseline: the race on HRH3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Harmony Biosciences ManagementPitolisant (HBS-301)
Histamine H3 receptor inverse agonist
HRH3Phase 3Prader-Willi Syndrome; Idiopathic Hypersomnia; EDS; Autism Spectrum DisorderApr 2027
Suven Life SciencesSuvn-G3031
Histamine H3 receptor inverse agonist
HRH3Phase 3NarcolepsyNov 2027

Conditions

Prader-Willi Syndrome (1) Idiopathic Hypersomnia (1) EDS (1) Autism Spectrum Disorder (1) Narcolepsy (1)

Modalities

protein or peptide (1), small molecule (1)

Companies

Harmony Biosciences Management (1) Suven Life Sciences (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.